Ann Arbor, Michigan 48105. CI-959, 5-methoxy-3-(1-methylethoxy)-N -1H-tetrazol-5-yl-benzo[b]thiophene-2-carboxamide, an anti-inflammatory agent, was considered for development as a treatment for rhinitis. Two-week topical nasal studies in Wistar rats and Beagle dogs were performed to assess nasal toxicity of CI-959. Rats were given daily doses in the right nostril of 0.05 ml of solutions of varying concentrations (0.5, 2, 10, 20, 30, 60, and 90 mg/ml; doses of 0.08, 0.3, 1.6, 3.2, 4.8, 9.6, and 14.6 mg/kg) of CI-959. Beagle dogs were given daily doses in the right nostril of 0.5 ml of 10, 20, 30, 60, and 90 mg/ml solutions (doses of 0.5, 0.8, 1.2, 2.8, and 3.7 mg/kg) of CI-959. Rats given &ge;60 mg/ml either lost weight or had decreased weight gain. Salivation at dosing was seen in both species. Four sections of nasal cavity were examined from each animal. In rats, 0.5 mg/ml was the "no effect" dose; minimal changes were seen at 2 mg/ ml, and significant changes were dose related in severity at &ge;10 mg/ml in all 4 nasal levels. Degeneration and necrosis of respiratory and olfactory epithelia were minimal to moderate in severity. Adhesions and fibro-osseous proliferation of ethmoturbinates, epithelial hyperplasia, squamous metaplasia, and exudate were also seen. In dogs, 10 mg/ml was the no effect dose; respiratory epithelium was affected at &ge;20 mg/ml. Respiratory epithelial degeneration was minimal to mild, with loss of ciliated and goblet cells and thinning of mucosa. Distribution of degeneration increased with increased concentrations. In both species, in accordance with the suggested action of CI-959, infiltration with neutrophils was not significant. CI-959 was locally toxic to nasal cavity respiratory and olfactory epithelia in rats and respiratory epithelium in dogs.
INTRODUCTION
CI-959, designated chemically as 5-methoxy-3-(1methylethoxy)-N-H-tetrazol-5-yl-benzo [b]thiophene-2carboxamide, monosodium salt, was being developed as a cell activation inhibitor. CI-959 selectively interrupts the stimulus-response-coupling mechanism involved in the activation of inflammatory cells (neutrophils, basophils, mast cells) with resultant inhibition of production and release of inflammatory mediators (superoxide, histamine, leukotriene, thromboxane) and initiation of cellular adhesion events. CI-959 is highly protein bound and is metabolized to 2 major metabolites. The half-life of the parent compound is 2 to 4 hr and that of metabolites is 6 to 15 hr. The majority of metabolites are excreted in urine over 8 to 24 hr. Because this profile suggests that CI-959 may have therapeutic value in the treatment of localized inflammation-driven diseases, we decided to assess its effects (via nasal instillation) on seasonal allergic rhinitis in humans. To this end, studies designed to assess the occurrence of nasal toxicity via topical administration were performed in Wistar rats and Beagle dogs.
MATERIALS AND METHODS
Rats. Random-bred, albino Wistar (Crl: [WI]BR) rats, purchased from Charles River Laboratories, were 85 to 127 days old and weighed 253 to 367 g at study initiation. All rats were acclimated to the laboratory environment before study initiation and were clinically normal before being assigned to dose groups ( 10/sex/dose). Rats were housed individually in stainless steel wire mesh cages and were given a measured portion (180 g) of Purina Certified Rodent Chow (5002) weekly with fresh water supplied ad libitum. Relative humidity and temperature of the animal room were maintained at 30-75% and 20.0-25.6°C, respectively. Based on results from exploratory and single-dose studies of CI-959 in rats, dosing concentrations of CI-959 were 0.5, 2, 10, 20, 30, 60, and 90 mg/ml (because of viscosity, concentrations >90 mg/ml were not usable). Weekly preparation of dosing solutions included dissolving CI-959 in saline and filtering it through 0.2-[Lm filters. Dosing volume was 0.05 ml (10) . All rats were given daily doses for 14 consecutive days in only the right nostril using a microliter pipette with a disposable tip covered with silicone tubing. The end of the tubing extended approximately 5 mm past the end of the pipette tip and formed the portion that was inserted into the nasal vestibule. Control rats received 0.05 ml of saline daily in the right nostril.
Rats were observed daily for signs of toxicity and were weighed pretest and on days 7 and 14. Food consumption was recorded weekly. Samples for determination of blood drug levels were taken via orbital bleeding from the first 5 rats per group approximately 6 min postdosing on days 1 and 14. Rats were euthanatized by CO2 inhalation and exsanguination. At necropsy, the following tissues were examined: lung, heart, thymus, esophagus, stomach, skin, urinary bladder, kidney, small intestine, large intestine, mammary gland, liver, pancreas, spleen, skeletal muscle, adrenals, eye, and lymph nodes. Testes, epididymides, prostate, and seminal vesicles were examined in male rats and ovaries, uterus, and vagina were examined in female rats. Nasal cavities from all animals were flushed with 10% buffered formalin via the nasopharynx before immersion in formalin, decalcified in formic acid (25%, v/ v), and grossly sectioned according to an established protocol (13) . Four sections (levels 1 to 4) of each nasal cavity were processed and embedded in paraffin, sectioned at 4 ~,m, stained with hematoxylin and eosin (H&E), and examined microscopically. Dogs. Beagle dogs were supplied by Marshall Farms USA, Inc. Dogs weighed 8 to 14 kg and were 1 to 3 yr old at initiation of the study. Dogs were housed individually in stainless steel cages, fed 150 to 350 g of Purina Certified Canine Diet (5007) daily with water provided ad libitum. Animal room environmental conditions were similar to those maintained for rats. All dogs were acclimated to the laboratory environment and judged to be acceptable on the basis of physical examination, hematology, and clinical chemistry before being placed in dose groups (2 dogs/sex/dose).
Dosing solutions were prepared as for rats. Based on the results of a single-dose study, dose concentrations of CI-959 were 10, 20, 30, 60, and 90 mg/ml. Dogs were given daily doses for 14 consecutive days of 0.5 ml dose solution in the right nostril using a pipette with a disposable tip. Dogs' heads were held in an extended position while dosing. Control animals were given 0.5 ml saline in the right nostril. Blood (2.5 ml) for determination of plasma drug concentration was taken by venipuncture predose and at 6, 15, 30, 60, and 120 min postdosing on day 1 and at 6 min postdosing on day 9.
Animals were observed daily for signs of toxicity and were weighed pretest and on day 14. Dogs were euthanatized by barbiturate injection and exsanguination. At necropsy, the following organs were examined from all dogs: lung, heart, thymus, esophagus, stomach, skin, liver, pancreas, urinary bladder, kidney, small intestine, large intestine, mammary gland, gallbladder, lymph node, skeletal muscle, spleen, adrenals, eye, and reproductive tract. Nasal cavities of each dog were flushed in a retrograde fashion with 10% buffered formalin, and the . eyes, integument, mandible, musculature of head, and brain were removed. Nasal cavities were further fixed by . immersion in 10% buffered formalin for at least 1 wk, 1 Slab sections (4 to 5 mm thick) of Fig. 1 ). Lines enclose areas from each slab section that were embedded and examined. Marker is divided in millimeters.
surface of section taken parallel to buccal surface of incisors ; (B) caudal surface of section taken rostral to first premolar; (C) caudal surface of section taken immediately rostral to third premolar; and (D) caudal surface of section taken immediately rostral to first molar. Level A section could be fitted into an embedding cassette, but levels B, C, and D were bisected immediately to the left of the septum, and the right side of each section was embedded. Level D was further divided into dorsal and ventral pieces. Sections were decalcified in formic acid, processed and embedded in paraffin, sectioned at 4 ~,m, stained with H&E, and examined microscopically. All studies in both species complied with U.S. Food and Drug Administration Good Laboratory Practice reg- ulations and were in accordance with the current guidelines for animal welfare (9, 12) .
RESULTS

Rats
There were no deaths. Increased frequency of salivation was dose related in all males at ?20 mg/ml and in all females at ~60 mg/ml. Over the 2-wk dosing period, body weight gain suppression (BWGS) of 74% in 60 mg/ ml female rats and of 79% in 90 mg/ml female rats was due mainly to statistically significant weight loss (approximately 20%) during week 1. BWGS was 20 and 24% in male rats at 60 and 90 mg/ml during week 1; over 2 wk, this suppression was approximately 9% for these groups. Mean plasma concentration of CI-959 generally increased with increasing doses of CI-959 (Table   I ).
Histopathologically, there was a dose-related increase in incidence, distribution, and severity of nasal mucosa lesions. No changes were observed at 0.5 mg/ml, and 2 of 10 female rats given 2 mg/ml had minimal unilateral foci of olfactory epithelial degeneration of dorsal ethmoturbinates (levels 3 and 4). Degeneration of nasal mucosa involving all 4 levels occurred in all rats given ± 10 mg/ml. Olfactory epithelium was affected at 10, 20, and 30 mg/ml, and respiratory and olfactory epithelia were affected at 60 and 90 mg/ml. Degeneration varied from minimal to moderate in severity and was characterized by disorganization of epithelia, intercellular edema, thinning of mucosa with or without cell sloughing, and necrosis (Fig. 3 ). Nasal mucosa necrosis was dose related in severity, with olfactory epithelium more adversely affected than other epithelia. The distribution of changes was random and varied from a few widely scattered foci to diffuse areas of nasal mucosa involvement. Degeneration and necrosis were observed on nasal septo-, max-illo-, and nasoturbinates; on ethmo-, endo-, and ectoturbinates ; and on the lateral walls of the dorsal, middle, and ventral meatus. Changes were predominantly unilateral in distribution at 10, 20, and 30 mg/ml and were bilateral at 60 and 90 mg/ml. Bilateral distribution of olfactory mucosal degeneration and necrosis was particularly evident in level 3 sections of the septal window. Changes accompanying mucosal degeneration and necrosis included respiratory epithelial hyperplasia with in- creased goblet cells and squamous metaplasia at ~! 10 mg/ ml, adhesions and fibro-osseous proliferation of ethmoturbinates at ~20 mg/ml (Fig. 4) , and serocellular luminal exudate at 60 and 90 mg/ml.
Dogs
There were no significant systemic clinical signs associated with daily intranasal administration of CI-959 for 2 wk. Clinical signs were limited to salivation in almost all dogs given CI-959. Day of onset and duration were highly variable and were not related to dose. There were no effects on body weight, food consumption, or body temperature. Mean plasma concentration of CI-959 generally increased with increasing doses and was highest at 6 min postdosing, decreasing to a tenth of the 6-min concentration within 120 min (Table II) . The disproportionately high concentration at 60 mg/ml on day I was no longer present on day 9 and, except for 20 and 60 mg/ml dose groups, concentrations on day 9 were slightly higher than on day 1. Table III illustrates maximum observed plasma concentration (Cmax) and area under plasma concentration time curve (AUC) on day 1. Histopathologically, effects on nasal epithelia were identified at ?20 mg/ml; there were no changes identified at 10 mg/ml. Levels C and D were affected; because of the normal variation of respiratory and transitional epithelia at level B, possible degeneration of respiratory epithelium with resolution to transitional epithelium could not be assessed. In control animals at level C, turbinates and septum were covered diffusely by ciliated respiratory epithelium with interspersed goblet cells (Fig. 5 ). At level D, turbinates were also covered mainly by respiratory epithelium; olfactory epithelium lined portions of dorsalmost scrolls and the roof of meatus only. Degeneration of respiratory epithelium occurred at ~20 mg/ml with dose-related extent of distribution. Degeneration was generally minimal to moderate and was characterized by loss of ciliated and goblet cells, with thinning of mucosa and resultant squamous or transitional appearance of epithelium ( Fig. 6 ). Degeneration was most extensive at 90 mg/ml and involved respiratory epithelia on turbinates, septum, and ventral surfaces of ventral meatus and nasopharynx ( Fig. 5 ). Anatomically, there was no site predilection for lesions on the dorsal or ventral scrolls or on dorsal, ventral, or lateral surfaces of scrolls. One animal had focal necrosis of the mucosa, with minimal fibrinopurulent inflammation on a turbinate at level C. At 60 mg/ml, degeneration affected smaller areas of respiratory epithelia than at 90 mg/ml. At 30 mg/ml, degeneration was minimal and widely scattered, affecting only level C or D in 2 dogs and both levels C and D in I dog; I dog was within normal limits. Two dogs from the 20-mg/ml dose group had multifocal minimal degeneration of respiratory epithelium with minimal polymorphonuclear infiltration on turbinates at level C.
DISCUSSION
In these studies, which were designed to assess the occurrence of toxicity on nasal mucosa, CI-959, an antiinflammatory drug candidate, induced degeneration of nasal respiratory and olfactory epithelia in rats at concentrations ~!2 mg/ml (0.3 mg/kg) and degeneration of nasal respiratory epithelium in dogs at concentrations >-20 mg/ml (1.0 mg/kg) when administered intranasally daily for 2 wk. Increasing concentrations of CI-959 were associated with increased severity and more extensive distribution of lesions. There was no apparent effect on nasal squamous or transitional epithelium. The intranasal no-adverse-effect dose (NAED) in rats (0.5 mg/ml; 0.08 mg/kg) was <0.2% of oral NAED in rats, and in dogs (10 mg/ml; 0.5 mg/kg) it was <2% of NAED in oral toxicity studies in dogs (K. Walsh, unpublished data). Systemic effects were not expected and were not identified in any animal. The lack of leukocyte response to extensive epithelial damage was attributed to the action of CI-959.
In the rat, as demonstrated by the distribution of lesions, deposition of a small volume of compound near the naris was adequate to achieve extensive distribution either by normal drainage or by inhalation. Reports of dye instillation studies in the rat in which a volume of 0.04 ml was used have demonstrated that instilled materials were deposited mainly on the lateral wall, maxilloturbinate, and nasoturbinate, with lesser amounts on the septo-and ethmoturbinates (10) . The volume of doses ised in our studies were based on dose-volume projecions for human use (-~-0.15 mllnostril; approximate dosẽ olume-cavity volume ratio of 0.019), nasal volumes for ats and dogs, and concern regarding overloading of the iasal cavity, which would result in excess drainage and jastrointestinal exposure. Nasal volumes in rats and dogs iave been reported to be 0.4 and 20 ml, respectively (4); vith dose volumes of 0.05 ml in rats and 0.5 ml in dogs, he ratios of dose volume to nasal volume were 0.125 in ats and 0.025 in dogs.
The proposed route of administration of CI-959 for the treatment of rhinitis was nasal spray. Because of the difficulty of administering doses in the form of sprays in experimental animals, intranasal instillation of a measured aliquot was selected as the route of administration in these studies. When coverage of nasal cavity walls using nasal drops was compared with that obtained with use of nasal sprays, drops achieved greater coverage than sprays, with approximately 40% of the dose cleared with half-lives of 6-9 min (3). Changing the volume over a range of 0.1-0.75 ml had no effect on the extent of deposition. Intranasal instillation of aldehydes produced lesions similar to those caused by inhalation of formaldehyde (10) , suggesting that instillation can achieve adequate exposure for assessment of local toxicity. It has also been shown that blood concentrations of the drug obtained after nasal administration are identical to those obtained after intravenous administration (5) . Pharmacokinetic profiles of CI-959 given intranasally were similar to those expected with intravenous administration, with the highest plasma concentrations occurring within minutes of dosing and with rapid decreases in plasma concentration occurring in a short period of time.
The difference in effects on olfactory epithelium between rats and dogs suggests species susceptibility for toxicity of olfactory nasal mucosa. This may be related to differences in dose volume, in nasal cavity anatomy, in nasal epithelial enzyme concentration, or in other factors. Dogs had one-fifth the dose volume-cavity volume ratio of rats; the volume for dogs was selected because it approximates the dose volume-nasal cavity volume of humans. The difference in effects on epithelium type may be due to the relatively greater surface covered by olfactory epithelium in rats than in dogs, although topography and morphology of the canine nasal mucosa are not as fully described as those of the rodent nasal cavity (6) . Sampling of canine nasal cavity in this study was limited and was based on easily identifiable oral landmarks to ensure standardization of samples and to provide sampling of all 4 epithelia. Although sampling may not have been optimal, the presence of lesions as far caudally as level D suggests that compound penetration was adequate, and the presence of lesions on dorsal and ventral surfaces of dorsal and ventral scrolls at that level suggests that the distribution was diffuse. However, olfactory epithelium was present mainly on the roof of the nasal cavity and dorsal scrolls at this level, and the possibility that the compound did not deposit on olfactory epithelium at this level in the dog cannot be excluded. More thorough sampling of canine nasal cavity and mapping of normal epithelial topography could answer some of these questions.
The fact that olfactory epithelium was affected more than respiratory epithelium in rats given CI-959 agrees with the theory that olfactory mucosa is more sensitive to materials that can be metabolized because of its higher enzyme activity (4, 7, 8) . Cytochrome P-450 concentration of respiratory mucosa in rat is 25°7o that of olfactory epithelium (11) . CI-959 is metabolized by P-450 enzymes to a metabolite that is slightly less active than the parent compound, and toxicity in the olfactory epithelium may be due to the presence of both parent and metabolite in localized high concentrations.
Reversibility of CI-959-induced changes was not assessed in these studies. However, in an exploratory doserange-finding (single-dose) rat study, proliferation of respiratory and olfactory epithelia was detected by 72 hr postdosing (C. Courtney, unpublished observation). Squamous metaplasia of respiratory epithelium suggests that repair is occurring, and it is unknown whether normal structure and function would eventually be restored if the drug were withdrawn. It has been suggested that the olfactory primary neuron is replaced when damaged by regeneration of perikaryon and axon via proliferation and differentiation of basal cells into neurons within 30 days of insult (2, 4) , so the possibility of regeneration cannot be excluded.
The fact that CI-959 affects the inflammatory response was evidenced by the lack of inflammatory cell infiltrate in areas of ulcers and epithelial necrosis. Fibro-osseous proliferation of nasal turbinates has been reported with compounds that are toxic to olfactory epithelium and has been attributed to extensive damage and inflammation (7, 8) , but turbinate changes were not identified in rats given the sialodacryoadenitis virus that induced extensive respiratory and olfactory epithelial damage and inflammation ( 1 ) . In our study, in rats with bony proliferations of turbinates, there was minimal inflammation within areas of extensive olfactory damage, suggesting that inflammation plays a minor role and that an as-yet-unidentified mechanism is responsible for turbinate bone changes.
